← Back to Clinical Trials
Recruiting NCT06371833

PRIMA EU Retrospective & Prospective

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Arthroplasty
Sponsor Limacorporate S.p.a
Study Type OBSERVATIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-10-25
Completion 2026-12
Interventions
Shoulder Arthroplasy with PRIMA humeral stem

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This clinical study aims at evaluating clinical, radiographic and patient-reported outcomes after total anatomic or reverse shoulder replacement using PRIMA humeral stem up to 24 months after surgery, in order to assess the short-term performance of the implant. Furthermore, the objective is also to collect short-term data on the survivorship of the implant and the incidence of complications.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 18 years old; 2. Full skeletal maturity; 3. Life expectancy over 24 months; 4. Patient's joint anatomically and structurally suited to receive the selected implants and functional deltoid muscle; 5. Patient meets at least one of the following indications: For Anatomic configuration: * non-inflammatory degenerative joint disease (i.e., osteoarthritis); * inflammatory arthritis of the glenohumeral joint including rheumatoid arthritis; * avascular necrosis of the humeral head; * cuff tear arthropathy (CTA Heads only); For Reverse configuration: * rotator cuff tear arthropathy; * osteoarthritiswith rotator cuff tear; * rheumatoid arthritis with rotator cuff tear; * massive irreparable rotator cuff tear; 6. Patient is able to understand the conditions of the study, to comply with the prescribed rehabilitation as well as willing to perform all scheduled follow-up visits; 7. Patient has signed the Informed Consent form previously approved by the Ethics Committee b

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}